Company intelligence / Profile preview

Iconix Biosciences

Mountain View, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Iconix was an early leader in toxicogenomics, providing a unique reference database (DrugMatrix) for gene expression-based safety assessment in drug discovery, enabling faster, more predictive toxicity evaluation for hundreds of compounds, and partnered with the FDA and leading pharmas. No clinical therapeutic products, but commercial products/services in toxicology reference and molecular diagnosis of drug-induced toxicity

Therapeutic areas: HematologyGastroenterologyNephrology
Modalities: Molecular diagnosticsGenomicsmRNA-based expression analysisProtein analysisMetabolite analysis
Industry: Molecular Diagnostics

Partnerships

AffymetrixGE HealthcareBristol Myers SquibbAbbott LaboratoriesEli LillyFDA (DrugMatrix deployment/CDER collaboration)

Beyond the preview

Go deeper on Iconix Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iconix Biosciences.

Explore the full profile